COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 815: Articles 8141-8150  | Next

Burden of PCR-Confirmed SARS-CoV-2 Reinfection in the U.S. Veterans Administration, March 2020 - January 2022
VA COVID-19 Observational Research Collaboratory, , Iwashyna, T. J.
10.1101/2022.03.20.22272571 — Posted: 2022-03-23
Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
Woodbridge, Y., Amit, S., Huppert, A., Kopelman, N. M.
10.1101/2022.03.20.22272549 — Posted: 2022-03-23
Acceptance of COVID-19 vaccine among healthcare workers in Katsina state, Northwest Nigeria
Abubakar, A. T., Suleiman, K., Ahmad, S. I., Suleiman, S. Y., Ibrahim, U. B., Suleiman, B. A., Haladu, S. A., Al-Mustapha, A. I., Abubakar, M. I.
10.1101/2022.03.20.22272677 — Posted: 2022-03-22
Post- intravitreal injection endophthalmitis pattern during the COVID-19 pandemic with implementation of patient masking
Mirghorbani, M., Bazvand, F., Riazi Esfahani, H., Mehrabi Bahar, M., Yaseri, M., Zarei, M.
10.1101/2022.03.19.22272419 — Posted: 2022-03-22
A potent SARS-CoV-2 antibody neutralizes Omicron variant by disassembling the spike trimer
Sun, L., Zhan, W., Tian, X., Zhang, X., Xing, S., Song, W., Liu, Q., Hao, A., Hu, Y., Zhang, M., Chen, Z., Ying, T., Lan, F.
10.1101/2022.03.21.485243 — Posted: 2022-03-22
A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 delta variant in transgenic K18-hACE2 mice
Brandys, P., Montagutelli, X., Merenkova, I., Barut, G. T., Thiel, V., Schork, N. J., Trüeb, B., Conquet, L., Deng, A., Antanasijevic, A., Lee, H.-K., Valiere, M., Sindhu, A., Singh, G., Herold, J.
10.1101/2022.03.21.485224 — Posted: 2022-03-22
ACE2 is necessary for SARS-CoV-2 infection and sensing by macrophages but not sufficient for productive viral replication
Labzin, L. I., Chew, K. Y., Wang, X., Esposito, T., Stocks, C. J., Rae, J., Yordanov, T., Holley, C. L., Emming, S., Fritzlar, S., Mordant, F. L., Steinfort, D. P., Subbarao, K., Lagendijk, A. K., Parton, R., Short, K. R., Londrigan, S. L., Schroder, K.
10.1101/2022.03.22.485248 — Posted: 2022-03-22
Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
Chuang, S.-T., Papp, H., Kuczmog, A., Eells, R., Condor Capcha, J. M., Shehadeh, L. A., Jakab, F., Buchwald, P.
10.1101/2022.03.22.485299 — Posted: 2022-03-22
Maximum likelihood pandemic-scale phylogenetics
De Maio, N., Kalaghatgi, P., Turakhia, Y., Corbett-Detig, R., Minh, B. Q., Goldman, N.
10.1101/2022.03.22.485312 — Posted: 2022-03-22
Rapid genotyping of viral samples using Illumina short-read sequencing data
Varadi, A., Kaszab, E., Kardos, G., Prepost, E., Szarka, K., Laczko, L.
10.1101/2022.03.21.485184 — Posted: 2022-03-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).